Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | IDH2 | P48735 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1391837 | 0.78 | MEN1 (0.46) | MEN1KMT2AMAPTNPSR1ALDH1A1 | |
| SCHEMBL1391540 | 0.78 | IDH2 (0.81) | MAPTMAPK1IDH2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1391637 | 0.77 | IDH2 (0.79) | MAPTMAPK1IDH2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3103521 | 0.77 | IDH2 (0.79) | MAPTMAPK1IDH2SMN1; SMN2 | |
| SCHEMBL1391736 | 0.76 | MAPT (0.70) | PDE4BPDE4DMEN1KMT2AMAPT | |
| SCHEMBL21940528 | 0.76 | RAB9A (0.67) | PDE4BPDE4DMEN1KMT2AMAPT | |
| SCHEMBL19053521 | 0.76 | NPSR1 (0.60) | PDE4BPDE4DMEN1KMT2AMAPT | |
| SCHEMBL19053262 | 0.75 | NPSR1 (0.59) | PDE4BPDE4DMEN1KMT2AMAPT | |
| SCHEMBL19053277 | 0.75 | POLB (0.67) | PDE4BPDE4DMEN1KMT2AMAPT | |
| SCHEMBL14274165 | 0.75 | CTSL (0.59) | MEN1KMT2AMAPTNPSR1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2231624-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | Progenics Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009091388-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | HAVCR2, ZC3HAV1, MAVS | PDE4B 3902/4885PDE4D 4666/4885MEN1 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.